 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChemCID | |
| Chemical and physical data | |
| Formula | C22H29NO3 |
| Molar mass | 355.478 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
KLS-13019 is acannabidiol derivative that has been modified on the side chain to improvesolubility and tissue penetration properties. It was developed and patented byNeuropathix subsidiaryKannalife and found to be 50x more potent than cannabidiol as aneuroprotective agent, thought to be mediated by modulation of themitochondrialsodium-calcium exchanger andGPR55. It also had a highertherapeutic index than cannabidiol.[1][2][3] Both KLS-13019 and cannabidiol, prevented the development ofCIPN, while only KLS-13019 uniquely reversedneuropathic pain fromchemotherapy. KLS-13019 binds to fewer biological targets than cannabidiol and KLS-13019 may possess the unique ability to reverse addictive behaviour, an effect not observed with cannabidiol.[4] Recent studies have also demonstrated that KLS-13019 influences neuroinflammatory responses in primary neuronal cultures, an effect that is dependent on the fatty acyl composition oflysophosphatidylinositol. This suggests an interaction between KLS-13019 and lipid signaling pathways, potentially involvingGPR55, a receptor implicated in neuroinflammatory modulation.[5]
 | Thiscannabinoid related article is astub. You can help Wikipedia byexpanding it. |